ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Astellas has teamed with Cambridge, Mass.-based biotech firm Proteostasis Therapeutics to develop drugs that modulate the body’s response to stress caused by an accumulation of unfolded proteins inside cells. The companies will jointly develop compounds against an undisclosed genetic disease but could expand their pact to explore other indications. Astellas will shell out an undisclosed up-front fee and research funding. If a drug reaches the market, Proteostasis could see overall payments exceeding $400 million.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter